Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
出版年份 2021 全文链接
标题
Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer
作者
关键词
-
出版物
Journal for ImmunoTherapy of Cancer
Volume 9, Issue 3, Pages e001865
出版商
BMJ
发表日期
2021-03-19
DOI
10.1136/jitc-2020-001865
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Expanding access to lung cancer clinical trials by reducing the use of restrictive exclusion criteria: Perspectives of a multi-stakeholder working group
- (2020) Patrick M. Forde et al. Clinical Lung Cancer
- CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
- (2020) Enriqueta Felip et al. EUROPEAN JOURNAL OF CANCER
- Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
- (2020) Gary Middleton et al. Lancet Respiratory Medicine
- Clinical Outcomes of Patients with Advanced Cancer and Pre‐Existing Autoimmune Diseases Treated with Anti‐Programmed Death‐1 Immunotherapy: A Real‐World Transverse Study
- (2019) Alessio Cortellini et al. ONCOLOGIST
- Immunotherapy in Non–Small-Cell Lung Cancer Patients With Performance Status 2: Clinical Decision Making With Scant Evidence
- (2019) Antonio Passaro et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged ≥70 Years or with Poor Performance Status (CheckMate 153)
- (2019) David R. Spigel et al. Journal of Thoracic Oncology
- Italian Cohort of Nivolumab Expanded Access Program in Squamous Non‐Small Cell Lung Cancer: Results from a Real‐World Population
- (2019) Lucio Crinò et al. ONCOLOGIST
- Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study
- (2019) Natasha B Leighl et al. Lancet Respiratory Medicine
- Retreatment With Anti-PD-L1 Antibody in Advanced Non-small Cell Lung Cancer Previously Treated With Anti-PD-1 Antibodies
- (2019) KOHEI FUJITA et al. ANTICANCER RESEARCH
- Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting
- (2019) Jason C Simeone et al. Future Oncology
- Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1–positive advanced non–small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies
- (2019) Kaname Nosaki et al. LUNG CANCER
- LBA1 Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study
- (2019) R S Herbst et al. ANNALS OF ONCOLOGY
- Immune checkpoint blockade for non–small cell lung cancer: What is the role in the special populations?
- (2019) R. Califano et al. EUROPEAN JOURNAL OF CANCER
- Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer
- (2019) Hisao Imai et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
- (2018) François-Xavier Danlos et al. EUROPEAN JOURNAL OF CANCER
- Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis
- (2018) Sandhya Manohar et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
- OUP accepted manuscript
- (2018) ANNALS OF ONCOLOGY
- Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression
- (2018) A. Bernard-Tessier et al. EUROPEAN JOURNAL OF CANCER
- Immune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer
- (2018) Maiko Niki et al. Oncotarget
- P1.06-020 Prevalence of Autoimmune Disease in US Veterans With Non-Small Cell Lung Cancer (NSCLC)
- (2017) Manali Patel et al. Journal of Thoracic Oncology
- P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153
- (2017) David Spigel et al. Journal of Thoracic Oncology
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
- (2017) Peng-Fei Wang et al. Frontiers in Pharmacology
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of Poor Performance Status in Lung Cancer Patients: Implications for Research
- (2008) Rogerio C. Lilenbaum et al. Journal of Thoracic Oncology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started